Randomization and blinding address different sources of bias. This trial used the first but not the second, an important distinction for symptom-based outcomes. Primary study
Design and reported result
Twenty-four patients with severe fibromyalgia and low IGF-1 were randomized to standard therapy with or without added growth hormone for one year. The study was open label and controlled by best available care rather than placebo injections. Tender-point and symptom-related measures favored the add-on group. No participant discontinued because of adverse events. Primary report
Our appraisal: an add-on strategy is the unit of comparison
The tested contrast was growth hormone added to ongoing care versus ongoing care alone. It does not isolate growth hormone from every feature of the treatment experience, including additional attention, expectations, and awareness of receiving an intervention.
Those issues are especially relevant when patients report symptoms or an examiner assesses tenderness. Randomization can help balance baseline factors, but it does not prevent knowledge of assignment from affecting subsequent behavior or measurement.
Standard care should also be described. Changes in accompanying treatment, adherence, and contact frequency can influence interpretation. An add-on result should not be relabeled as evidence that the experimental intervention replaces usual care.
Small trials provide limited information about uncommon harms. “No discontinuation due to adverse events” means that particular outcome was not observed; it does not mean no adverse effects occurred or that long-term safety was established.
The pilot offers a hypothesis-generating signal and practical information for designing more rigorous studies. It does not provide a definitive treatment estimate for all fibromyalgia patients. Full review should inspect allocation, assessor procedures, concomitant-care changes, missing observations, prespecified outcomes, and adverse-event detail. The open-label design should remain visible wherever its favorable findings are summarized.
Frequently asked questions
Was treatment randomized?
Yes.
Was it blinded?
No; the trial was open label.
Did both groups receive standard care?
Yes.
Was the comparator a matched placebo injection?
No.
Does no adverse-event discontinuation establish no adverse effects?
No.
Can this establish replacement of standard therapy?
No.
What is the main design limitation for symptom outcomes?
Knowledge of treatment assignment could influence reporting or assessment.